Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Change in Taxes (2018 - 2025)

Historic Change in Taxes for Takeda Pharmaceutical (TKPHF) over the last 6 years, with Q1 2025 value amounting to -$27.5 million.

  • Takeda Pharmaceutical's Change in Taxes rose 9083.56% to -$27.5 million in Q1 2025 from the same period last year, while for Mar 2025 it was -$612.1 million, marking a year-over-year decrease of 939.23%. This contributed to the annual value of $439.5 million for FY2025, which is 16933.47% up from last year.
  • According to the latest figures from Q1 2025, Takeda Pharmaceutical's Change in Taxes is -$27.5 million, which was up 9083.56% from $16.9 million recorded in Q4 2024.
  • Over the past 5 years, Takeda Pharmaceutical's Change in Taxes peaked at $126.8 million during Q1 2023, and registered a low of -$301.0 million during Q4 2023.
  • Its 4-year average for Change in Taxes is -$95.0 million, with a median of -$56.2 million in 2022.
  • Within the past 5 years, the most significant YoY rise in Takeda Pharmaceutical's Change in Taxes was 10562.01% (2024), while the steepest drop was 33687.02% (2024).
  • Takeda Pharmaceutical's Change in Taxes (Quarter) stood at -$84.9 million in 2022, then tumbled by 254.52% to -$301.0 million in 2023, then skyrocketed by 105.62% to $16.9 million in 2024, then crashed by 262.76% to -$27.5 million in 2025.
  • Its Change in Taxes stands at -$27.5 million for Q1 2025, versus $16.9 million for Q4 2024 and -$300.5 million for Q1 2024.